Moxifloxacin Prophylaxis against MDR TB, New York, New York, USA

Emerg Infect Dis. 2015 Mar;21(3):500-3. doi: 10.3201/eid2103.141313.

Abstract

Contacts of persons infected with multidrug-resistant tuberculosis (MDR TB) have few prophylaxis options. Of 50 contacts of HIV- and MDR TB-positive persons who were treated with moxifloxacin, 30 completed treatment and 3 discontinued treatment because of gastrointestinal symptoms. Moxifloxacin was generally well-tolerated; further research of its efficacy against MDR TB is needed.

MeSH terms

  • Antibiotic Prophylaxis*
  • Antitubercular Agents / therapeutic use*
  • Coinfection
  • Fluoroquinolones / therapeutic use*
  • Follow-Up Studies
  • HIV Infections
  • Humans
  • Moxifloxacin
  • Mycobacterium tuberculosis
  • New York City / epidemiology
  • Treatment Outcome
  • Tuberculosis, Multidrug-Resistant / drug therapy*
  • Tuberculosis, Multidrug-Resistant / epidemiology
  • Tuberculosis, Multidrug-Resistant / prevention & control

Substances

  • Antitubercular Agents
  • Fluoroquinolones
  • Moxifloxacin